Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
Publication
, Journal Article
Farnier, M; Dong, Q; Shah, A; Johnson-Levonas, AO; Brudi, P
Published in: Lipids in Health and Disease
2011
Duke Scholars
Published In
Lipids in Health and Disease
DOI
ISSN
1476-511X
Publication Date
2011
Volume
10
Issue
1
Start / End Page
212 / 212
Publisher
Springer Science and Business Media LLC
Related Subject Headings
- Nutrition & Dietetics
- 3210 Nutrition and dietetics
- 3205 Medical biochemistry and metabolomics
- 1111 Nutrition and Dietetics
- 1101 Medical Biochemistry and Metabolomics
- 0899 Other Information and Computing Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Farnier, M., Dong, Q., Shah, A., Johnson-Levonas, A. O., & Brudi, P. (2011). Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. Lipids in Health and Disease, 10(1), 212–212. https://doi.org/10.1186/1476-511x-10-212
Farnier, Michel, Qian Dong, Arvind Shah, Amy O. Johnson-Levonas, and Philippe Brudi. “Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.” Lipids in Health and Disease 10, no. 1 (2011): 212–212. https://doi.org/10.1186/1476-511x-10-212.
Farnier M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P. Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. Lipids in Health and Disease. 2011;10(1):212–212.
Farnier, Michel, et al. “Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.” Lipids in Health and Disease, vol. 10, no. 1, Springer Science and Business Media LLC, 2011, pp. 212–212. Crossref, doi:10.1186/1476-511x-10-212.
Farnier M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P. Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. Lipids in Health and Disease. Springer Science and Business Media LLC; 2011;10(1):212–212.
Published In
Lipids in Health and Disease
DOI
ISSN
1476-511X
Publication Date
2011
Volume
10
Issue
1
Start / End Page
212 / 212
Publisher
Springer Science and Business Media LLC
Related Subject Headings
- Nutrition & Dietetics
- 3210 Nutrition and dietetics
- 3205 Medical biochemistry and metabolomics
- 1111 Nutrition and Dietetics
- 1101 Medical Biochemistry and Metabolomics
- 0899 Other Information and Computing Sciences